Investment Summary |
|
|---|---|
| Date | 2020-05-06 |
| Target | Everest Medicines |
| Sector | Life Science |
| Investor(s) |
HBM Partners AG
Janus Henderson |
| Deal Type | Venture |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Private Equity Firm |
|---|---|
| Founded | 2001 |
| PE ASSETS | 3.0B USD |
| Size | Mega |
| Type | Sector Focused |
HBM Partners is a private investment firm focused on investing in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. HBM looks to invest $5 to $50 million per transaction and will consider private and public companies. HBM Partners was established in 2001 and is headquartered in Zug, Switzerland.
| DEAL STATS | # |
|---|---|
| Overall | 35 of 66 |
| Sector (Life Science) | 28 of 57 |
| Type (Venture) | 26 of 53 |
| Country (China) | 4 of 7 |
| Year (2020) | 4 of 17 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-04-01 |
iTeos Therapeutics
Watertown, Massachusetts, United States iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates with an aim to improve the clinical benefit of oncology therapies. iTeos Therapeutics was founded in 2011 and is based in Watertown, Massachusetts. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-06-01 |
Instil Bio
Dallas, Texas, United States Instil Bio is a global, clinical-stage cell therapy company developing tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. The company is building on the decades-long foundation of TIL efficacy in treating solid tumors, applying their cell therapy experience and TIL manufacturing platform to bring the promise of TIL therapy to patients in need. Instil Bio was founded in 2018 and is based in Dallas, Texas. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 1934 |
| Sector | Financial Services |
| Employees | 2,144 |
| Revenue | 2.1B USD (2023) |
Janus Henderson is a provider of investment solutions across a range of asset classes, including growth, core and value equities, fixed income, and mathematical investing. Janus Henderson was founded in 1934 and is based in London, England.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 4 |
| Sector (Life Science) | 1 of 1 |
| Type (Venture) | 1 of 1 |
| Country (China) | 1 of 1 |
| Year (2020) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-05-31 |
Henderson Group
London, United Kingdom Henderson Global Investors (Henderson) is an independent global asset management firm. Henderson Group was founded in 1934 and is based in London, United Kingdom. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-10-09 |
Everest Medicines
Shanghai, China Everest Medicines is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other Asian markets. Everest Medicines was founded in 2017 and is based in Shanghai, China. |
Sell | - |
